Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KALV – KalVista Pharmaceuticals Inc

Float Short %

38.26

Margin Of Safety %

Put/Call OI Ratio

2.37

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

16.86

Target Price

31

Analyst Recom

1

Performance Q

8.01

Relative Volume

0.53

Beta

-0.15

Ticker: KALV




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10KALV10.90.910.0014754
2025-11-11KALV11.480.8540.9115311
2025-11-12KALV13.361.450.0120351
2025-11-13KALV13.111.450.0020350
2025-11-14KALV13.621.450.0020349
2025-11-17KALV14.851.450.0020357
2025-11-18KALV14.251.290.3621369
2025-11-19KALV13.691.290.0021384
2025-11-20KALV13.021.290.0121397
2025-11-21KALV13.111.040.0023712
2025-11-24KALV13.381.270.2820992
2025-11-25KALV13.261.275.3821010
2025-11-26KALV14.11.27244.5921061
2025-12-01KALV13.92.360.1031078
2025-12-02KALV13.532.220.7731758
2025-12-03KALV14.642.220.1431761
2025-12-04KALV16.42.320.0331654
2025-12-05KALV16.462.280.0031816
2025-12-08KALV16.882.370.1631446
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10KALV10.89-16.5- -3.79
2025-11-11KALV11.47-16.5- -3.79
2025-11-12KALV13.36-16.5- -3.79
2025-11-13KALV13.10-16.5- -3.79
2025-11-14KALV13.62-19.8- -4.06
2025-11-17KALV14.84-19.8- -4.06
2025-11-18KALV14.26-19.8- -4.06
2025-11-19KALV13.71-19.8- -4.06
2025-11-20KALV13.02-19.8- -4.06
2025-11-21KALV13.10- - -
2025-11-24KALV13.38- - -
2025-11-25KALV13.28- - -
2025-11-26KALV14.11- - -
2025-12-01KALV13.91- - -
2025-12-02KALV13.52- - -
2025-12-03KALV14.66- - -
2025-12-04KALV16.41- - -
2025-12-05KALV16.43- - -
2025-12-08KALV16.86- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10KALV-1.090.5038.42
2025-11-11KALV-1.080.5038.42
2025-11-12KALV-1.080.5035.32
2025-11-13KALV-1.110.5035.31
2025-11-14KALV-1.110.5035.05
2025-11-17KALV-1.135.6335.16
2025-11-18KALV-1.125.6335.16
2025-11-19KALV-1.205.6335.16
2025-11-20KALV-1.205.6335.16
2025-11-21KALV-1.135.6335.16
2025-11-24KALV-1.015.2235.17
2025-11-25KALV-1.015.2235.17
2025-11-26KALV-1.015.2238.14
2025-12-01KALV-1.174.3238.23
2025-12-02KALV-1.174.3238.26
2025-12-03KALV-1.164.3238.26
2025-12-04KALV-1.194.3238.26
2025-12-05KALV-1.194.3238.26
2025-12-08KALV-1.195.2538.26
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.76

Avg. EPS Est. Next Quarter

-0.61

Insider Transactions

-1.19

Institutional Transactions

5.25

Beta

-0.15

Average Sales Estimate Current Quarter

20

Average Sales Estimate Next Quarter

28

Fair Value

Quality Score

18

Growth Score

25

Sentiment Score

82

Actual DrawDown %

62.5

Max Drawdown 5-Year %

-90.1

Target Price

31

P/E

Forward P/E

18.53

PEG

P/S

595.95

P/B

50.13

P/Free Cash Flow

EPS

-4

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

-2.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14242.57

Relative Volume

0.53

Return on Equity vs Sector %

-524.8

Return on Equity vs Industry %

-509.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

KalVista Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 270
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
stock quote shares KALV – KalVista Pharmaceuticals Inc Stock Price stock today
news today KALV – KalVista Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch KALV – KalVista Pharmaceuticals Inc yahoo finance google finance
stock history KALV – KalVista Pharmaceuticals Inc invest stock market
stock prices KALV premarket after hours
ticker KALV fair value insiders trading